Company Overview and News

 
Vestas and MHI Vestas Offshore Wind change setup on Isle of Wight to make room for future offshore expansion

16h globenewswire
As part of their firm commitment to the UK wind market and their presence on the Isle of Wight, Vestas is relocating its testing related activities at West Medina Mills to the nearby St. Cross facility on Isle of Wight to make room for future expansion under consideration by MHI Vestas Offshore Wind.
MHVYF VWSYF VWDRY 7011

81
10 Best High-Growth Stocks for Young Investors

2018-09-17 investorplace - 3
No investment strategy suits all the people all the time. This is particularly true for young investors in their 20s and 30s. Youth not only has social advantages; it can provide significant margin for your portfolio to grow. As such, high-growth stocks are ideal for the young-adult, millennial demographic.
SQ GE GEC MHVYF ACBFF K CTRL CVNA M CGC GLD CMG VYGR ACB AMZN KGC O87 WEED GNE TNET 7011

 
Mitsubishi Heavy to invest additional ¥200 billion in MRJ

2018-09-16 japantimes.co.jp
Mitsubishi Heavy Industries plans to invest ¥200 billion in the development of Mitsubishi Regional Jet, sources said.
MHVYF 7011

 
JR Tokai sets up unit in Texas with eye on orders for the state’s bullet train project

2018-09-05 japantimes.co.jp
NAGOYA – Central Japan Railway Co. (JR Tokai), has set up a wholly owned subsidiary in Dallas in an effort to win orders related to a project to build a high-speed railway in Texas.
9022 MHVYF 6501 HTHIY 7011

1
Rocket Propulsion Market worth $6.36 Bn by 2023

2018-09-05 asdnews
According to the new market research report, now available on ASDReports, "Rocket Propulsion Market by Type (Rocket Motor, Rocket Engine), Orbit (LEO, MEO, GEO, Beyond GEO), Launch Vehicle Type (Manned, Unmanned), End User (Military & Government, Commercial), Propulsion Type, Component, Region - Global Forecast to 2023", The rocket propulsion market is estimated to be USD 4.23 billion in 2018 and is projected to reach USD 6.
MHVYF 7011 OA

 
Mitsubishi Heavy Industries to enter European luxury ferry market following restructuring

2018-09-04 japantimes.co.jp
Mitsubishi Heavy Industries will enter the luxury ferry market in Europe as part of a restructuring of its ship-building business.
MHVYF 7011

 
MHI Vestas Offshore Wind har modtaget en 860 MW-ordre i England

2018-09-03 globenewswire
MHI Vestas Offshore Wind har modtaget en fast og ubetinget ordre på Triton Knoll offshoreprojektet i England på 860 MW, jf. Vestas Wind Systems A/S’ Selskabsmeddelelse nr. 26/2018 af 10. august 2018. Ordren er placeret af Triton Knoll Offshore Wind Farm Ltd. og består af 90 stk. V164-9.5 MW-møller.
MHVYF VWSYF VWDRY 7011

 
MHI Vestas Offshore Wind has received an 860 MW order in the UK

2018-09-03 globenewswire
With reference to Vestas Wind Systems A/S’ Company announcement No. 26/2018 of 10 August 2018, MHI Vestas Offshore Wind has received a firm and unconditional order for the 860 MW Triton Knoll offshore project in the UK. The order has been placed by Triton Knoll Offshore Wind Farm Ltd. and comprises 90 V164-9.5 MW turbines.
MHVYF VWSYF VWDRY 7011

 
Mitsubishi Heavy Industries to enter European luxury ferry market following restructuring

2018-09-03 japantimes.co.jp
Mitsubishi Heavy Industries Ltd. will enter the luxury ferry market in Europe as part of a restructuring of its ship-building business.
MHVYF 7011

 
First Take (Sept. 3, 2018)

2018-08-30 aviationweek
DEFENSE Lockheed Martin has offered Japan an F-22 derivative with a large wing and greatly increased, 1,400-nm combat radius, The Nikkei newspaper says. Mitsubishi Heavy Industries would develop the wing, Mitsubishi Electric the avionics, and the aircraft could be powered by twin IHI XF9-1 engines, says Nikkei. Russia’s defense ministry has signed a contract with United Aircraft Corp. for an initial production batch of Sukhoi Su-57 fighters, for delivery in 2019.
MEL MHVYF MIELY 6503 MIELF 7011

 
Japan reveals major increase in US acquisitions

2018-08-23 janes
The Japanese Ministry of Defense (MoD) has revealed defence contracting statistics for recent years, showing a significant increase on spending on US military equipment and also a continuing high dependency on local contractor Mitsubishi Heavy Industries (MHI).
MHVYF KWHIF KWHIY 7012 7011

 
Lockheed Gives Japan More Than 50% of New Fighter Jet Work

2018-08-23 asdnews
TOKYO -- Lockheed Martin has proposed that Japanese companies be responsible for more than half of the development and production of a next-generation fighter jet that Japan wants to introduce in 2030, Nikkei learned Wednesday.
BAESY LMT MEL MHVYF MIELY 6503 MIELF BA BAESF 7011

 
MHI Vestas Offshore Wind has entered into a conditional agreement for a 950 MW offshore project in the UK  

2018-08-21 globenewswire
MHI Vestas Offshore Wind has entered into a conditional agreement for a 950 MW offshore project in the UK
MHVYF VWSYF VWDRY 7011

 
MHI Vestas Offshore Wind har indgået en betinget aftale om levering til et 950 MW offshoreprojekt i England

2018-08-21 globenewswire
MHI Vestas Offshore Wind har indgået en betinget aftale om levering til et 950 MW offshoreprojekt i England
MHVYF VWSYF VWDRY 7011

 
MHI Keeps Pushing Consolidation

2018-08-14 aviationweek
Mitsubishi Heavy Industries (MHI) is not dropping its idea to consolidate Japan’s aircraft industry. The industry ministry has backed the proposal as well, pointing to the prospective competitiveness in bidding for work in future aircraft programs. Meanwhile, MHI is undertaking independent initiatives to keep ahead of competitors in the aircraft business. For metal fabrication, the part of the business most exposed to low-wage competition, the company is increasing automation, says .
MHVYF 7011

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...